

**MINUTES OF THE September 14th, 2010
PHARMACY AND THERAPEUTICS (P & T) COMMITTEE MEETING**

MEMBERS ATTENDING: Hosan Azomani, M.D.; Joyce Brewer, Ph.D.; Sharon Dickey, Pharm.D.; Lonnie Hicks, R.Ph.; Deborah Minor, Pharm.D.; Carol Tingle, M.D.; Lee Voulters M.D.; Wilma Wilbanks, R.Ph.

Also present: Judith Clark, R.Ph., Pharmacy Director, DOM; Terri Kirby, R.Ph., DOM; J. David Wuest, R.Ph., Provider Synergies

MEMBERS ABSENT: Billy Brown, Pharm.D.;

CALL TO ORDER: Dr. Minor called the meeting to order.

INTRODUCTIONS: Ms. Clark welcomed attendees to the meeting and asked everyone at the table to introduce themselves. She thanked the Committee members for their work and introduced the DOM pharmacy staff and attendees from DOM's other pharmacy vendors, HID and ACS. ACS staff participated in the meeting via tele-conference.

ADMINISTRATIVE MATTERS: Ms. Clark outlined procedural and safety guidelines for the meeting. She noted that the P&T Committee is an advisory Committee and that the DOM has the final say regarding the PDL. She stated that the PDL decisions for classes reviewed at this meeting would be effective on January 1, 2011 and that minutes from this meeting would be posted no later than October 14, 2010. She also stated that the State of Mississippi Medicaid Program, like other Medicaid agencies in the country, is in a serious financial situation. Ms. Clark stated that four new members would be joining the Committee and that two of them had been named and accepted the position. She went on to thank new appointee Ms. Wilbanks for participating in the Committee's activities and that Dr. Brown had accepted the position but due to timing was unable to attend this meeting.

DRUG CLASS ANNOUNCEMENTS: Ms. Clark stated that DOM and Provider Synergies continually review Drug classes for the PDL process based on the clinical and financial benefits of so doing. She informed the Committee that the Bile Salt class and the Cough and Cold classes, originally scheduled for meeting(s) earlier in 2010, are to be reviewed at this meeting. She provided the Committee with an overview on the current policy regarding Cough and Cold agents. The committee was instructed that there was no guarantee that DOM would alter their current policy regarding coverage of additional cough and cold preparations. However, the DOM was requesting the Committee's direction and recommendations. She thanked the Committee in advance for providing assistance in the class of medications.

APPROVAL OF MARCH 9TH, 2010 MEETING MINUTES: Dr. Minor asked for changes or a motion to approve the minutes from the April 13th, 2010 P&T Committee meeting. Dr. Brewer requested that three typographical errors and one motion omission be fixed. Dr. Brewer moved to approve the minutes. Mr. Hicks seconded the motion and the minutes were approved unanimously.

PRESENTATIONS BY ADVOCACY GROUPS: Dr. Holloman, UMC Department of Psychiatry, presented information to the Committee regarding mental health medications. Ms Tonya Tate, Executive Director of Mississippi NAMI, presented NAMI's position of open access for mental health drugs.

THERAPEUTIC CLASS REVIEWS: Mr. Wuest stated that he would be presenting new information not previously covered in the Committee's reviews.

ALZHEIMERS AGENTS

Mr. Wuest presented a brief overview of this class. Mr. Wuest presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
ARICEPT / ARICEPT ODT (ORAL)	ON	Yes
EXELON (TRANSDERM.)	ON	Yes
GALANTAMINE ER (ORAL)	OFF	No-Generic
GALANTAMINE (ORAL)	OFF	No-Generic
EXELON CAPSULES (ORAL)	ON	Yes
NAMENDA (ORAL)	ON	Yes
RIVASTIGMINE CAPSULES (ORAL)	OFF	No-Generic
EXELON SOLUTION (ORAL)	ON	Yes

No public testimony on this class was provided. Lee Ann Griffin, Pharm.D. from Pfizer yielded her time for Aricept. Barbara Wagner from Forest yielded her time for Namenda.

Dr. Azomani made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Voulters. The motion passed unanimously.

ANTIBIOTICS, VAGINAL

Mr. Wuest noted that this class has no new agents in it since the last time the Committee reviewed it. He provided an overview of the class.

Mr. Wuest presented the PDL recommendations for the class.

Brand Name	Current PDL Status	PDL Recommendation
VANDAZOLE (VAGINAL)	ON	Yes
CLINDAMYCIN (VAGINAL)	ON	Yes-Generic
METRONIDAZOLE (VAGINAL)	ON	Yes-Generic
CLEOCIN OVULES (VAGINAL)	ON	Yes
CLINDESSE (VAGINAL)	OFF	No

No public testimony on this class was provided.

Dr. Brewer made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Dickey. The motion passed unanimously.

ANTIDEPRESSANTS, OTHER

Mr. Wuest presented a brief overview of the class including an explanation on why Marplan was being review and information on generic Venlafaxine ER products entry into market.

Mr. Wuest presented the following PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
TRAZODONE (ORAL)	ON	Yes-Generic
MARPLAN (ORAL)	NR	No
NEFAZODONE (ORAL)	ON	Yes-Generic
BUPROPION (ORAL)	ON	Yes-Generic
MIRTAZAPINE (ORAL)	ON	Yes
PARNATE (ORAL)	OFF	No
NARDIL (ORAL)	OFF	No
BUPROPION SR (ORAL)	ON	Yes-Generic
PRISTIQ (ORAL)	ON	Yes
VENLAFAXINE (ORAL)	OFF	No-Generic
OLEPTRO ER (ORAL)	OFF	No
EFFEXOR XR (ORAL)	ON	Yes
VENLAFAXINE ER CAPSULES (ORAL)	OFF	No-Generic
VENLAFAXINE ER TABLETS (ORAL)	OFF	No
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	OFF	No-Generic
BUPROPION XL (ORAL)	ON	Yes-Generic
TRANLYCYPROMINE SULFATE (ORAL)	OFF	No-Generic

APLENZIN (ORAL)	OFF	No
EMSAM (TRANSDERMAL)	OFF	No

Public testimony on this class was provided on behalf of Pfizer by Dr. Norton.

Dr. Tingle made a motion to accept the recommendations as presented. Dr. Voulters seconded the motion, which passed unanimously.

ANTIDEPRESSANTS, SSRIs

Mr. Wuest noted that this class has no new agents in it since the last time the Committee reviewed it. He provided a brief overview of the class including the moving of Cymbalta to the Fibromyalgia class.

Mr. Wuest presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
SERTRALINE (ORAL)	ON	Yes-Generic
CITALOPRAM (ORAL)	ON	Yes-Generic
FLUOXETINE (ORAL)	ON	Yes-Generic
PAROXETINE (ORAL)	ON	Yes-Generic
LEXAPRO (ORAL)	OFF	No
FLUVOXAMINE (ORAL)	ON	Yes-Generic
PEXEVA (ORAL)	OFF	No
FLUOXETINE WEEKLY (ORAL)	OFF	No-Generic
PAROXETINE CR (ORAL)	OFF	No-Generic
LUVOX CR (ORAL)	ON	Yes

No public testimony on this class was provided.

Dr. Voulters made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Azomani. The motion passed unanimously.

ANTIFUNGALS, ORAL

Mr. Wuest presented a brief overview of the class including clinical information about two new agents in this class, Oravig and Terbinex.

Mr. Wuest then presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
TERBINAFINE (ORAL)	ON	Yes-Generic
GRIS-PEG (ORAL)	ON	Yes
NYSTATIN (ORAL)	ON	Yes-Generic
FLUCONAZOLE (ORAL)	ON	Yes-Generic
KETOCONAZOLE (ORAL)	ON	Yes-Generic
CLOTRIMAZOLE (MUCOUS MEM)	ON	Yes-Generic
GRISEOFULVIN SUSPENSION (ORAL)	ON	Yes-Generic
GRIFULVIN V TABLETS (ORAL)	OFF	No
TERBINEX (MISCELL)	OFF	No
ORAVIG (BUCCAL)	OFF	No
LAMISIL GRANULES (ORAL)	OFF	No
ANCOBON (ORAL)	OFF	No
ITRACONAZOLE (ORAL)	OFF	No-Generic
VFEND (ORAL)	OFF	No
NOXAFIL (ORAL)	OFF	No

Public testimony on this class was provided on Oravig by Harry Novotny on behalf of Strativa.

Dr. Azomani made a motion to approve the recommendations as presented by Provider Synergies. The motion was seconded by Dr. Voulters and passed unanimously.

ANTIPSYCHOTICS

Mr. Wuest presented a brief overview of the class including information on new agents in this class regarding Fanapt and Saphris. Once again Injectable products were not reviewed.

Mr. Wuest presented the PDL recommendations for this class:

Brand Name	Current PDL Status	PDL Recommendation
THIOTHIXENE (ORAL)	ON	Yes-Generic
AMITRIPTYLINE / PERPHENAZINE (ORAL)	ON	Yes-Generic
FLUPHENAZINE (ORAL)	ON	Yes-Generic
CHLORPROMAZINE (ORAL)	ON	Yes-Generic
THIORIDAZINE (ORAL)	ON	Yes-Generic
HALOPERIDOL (ORAL)	ON	Yes-Generic
ORAP (ORAL)	OFF	No
TRIFLUOPERAZINE (ORAL)	ON	Yes-Generic
PERPHENAZINE (ORAL)	ON	Yes-Generic
RISPERIDONE (ORAL)	ON	Yes-Generic
MOBAN (ORAL)	ON	Yes
GEODON (ORAL)	ON	Yes
CLOZAPINE (ORAL)	ON	Yes-Generic
FANAPT (ORAL)	OFF	No
SAPHRIS (SUBLINGUAL)	ON	Yes
SEROQUEL (ORAL)	ON	Yes
SYMBYAX (ORAL)	OFF	No
ABILIFY (ORAL)	ON	Yes
SEROQUEL XR (ORAL)	ON	Yes
ZYPREXA (ORAL)	OFF	No
FAZACLO (ORAL)	OFF	No
INVEGA (ORAL)	OFF	No

Public testimony on this class was provided on Fanapt by Julia Compton, Pharm.D. on behalf of Novartis.

Bhrett McCabe, Ph.D. from BMS, Michelle Arledge Pharm.D. from Ortho-McNeil Janssen, Jann Johnson, Pharm.D. from Astra Zeneca, Jack Putman, M.D. from Merck, and Lee Ann Griffin, Pharm.D. from Pfizer yielded their time to the Committee.

Dr. Tingle made the motion to approve the recommendations as presented by Provider Synergies with the addition of Fanapt being preferred. The motion was seconded by Dr. Brewer and approved in a 7-1 vote with Dr. Azomani opposed.

ANTIVIRALS, ORAL

Mr. Wuest noted that this class has no new agents in it since the last time the Committee reviewed it. He provided an overview of the class.

Mr. Wuest presented the PDL recommendations:

Brand Name	Current PDL Status	PDL Recommendation
ACYCLOVIR (ORAL)	ON	Yes-Generic
VALACYCLOVIR (ORAL)	ON	Yes-Generic
VALTREX (ORAL)	ON	Yes
FAMVIR (ORAL)	OFF	No
FAMCICLOVIR (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Voulters made a motion to accept the recommendations as presented. This motion was seconded by Ms. Wilbanks. The motion passed unanimously.

BILE SALTS

Mr. Wuest presented an overview of the class which was a new class to the Committee.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
URSO (ORAL)	NA	Yes
URSODIOL (ORAL)	NA	Yes-Generic
ACTIGALL (ORAL)	NA	Yes
URSO FORTE (ORAL)	NA	Yes
CHENODAL (ORAL)	NA	No

No public testimony on this class was provided.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Brewer and passed unanimously.

CEPHALOSPORINS AND RELATED ANTIBIOTICS

Mr. Wuest presented overview of this therapeutic class. He discussed the rationale for continuing to review the class

Mr. Wuest made the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
CEPHALEXIN (ORAL)	ON	Yes-Generic
CEFUROXIME (ORAL)	ON	Yes-Generic
AUGMENTIN 125 SUSPENSION (ORAL)	ON	Yes
CEFADR.OXIL (ORAL)	ON	Yes-Generic
AUGMENTIN 250 SUSPENSION (ORAL)	ON	Yes
SUPRAX (ORAL)	ON	Yes
AMOXICILLIN/CLAV TABLET (ORAL)	ON	Yes-Generic
AMOXICILLIN/CLAV SUSPENSION (ORAL)	ON	Yes-Generic
CEFACTOR (ORAL)	ON	Yes-Generic
CEFPROZIL (ORAL)	ON	Yes-Generic
CEFTIN SUSPENSION (ORAL)	OFF	No
AUGMENTIN XR (ORAL)	ON	Yes
CEFDINIR (ORAL)	OFF	No-Generic
CEFPODOXIME (ORAL)	OFF	No-Generic
CEDAX (ORAL)	OFF	No
AMOXICILLIN/CLAV XR (ORAL)	ON	Yes-Generic
CEFTIN TABLETS (ORAL)	OFF	No
CEFDITOREN (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Dr. Brewer and passed unanimously.

COUGH AND COLD

Mr. Wuest presented a brief overview of the class. PDL recommendations were discussed but not presented.

Public testimony on this class was provided on Rymed and Ed-A Hist by Jim Smith on behalf of Edwards and on Zonatuss by Mary Ann Griffin, N.P. on behalf of Atley.

Ms. Clark asked the speakers several questions regarding ingredients and strengths of the products addressed in public testimony.

Dr. Voulters made a motion to table this item to allow more time for review. The motion was seconded by Dr. Brewer and passed unanimously by the Committee. This class will be re-presented at the October 2010 meeting.

FLUOROQUINOLONES, ORAL

Mr. Wuest presented an overview of the class. There were no new agents in this class since the last time the Committee review the class.

Mr. Wuest made the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
FACTIVE (ORAL)	OFF	No
CIPROFLOXACIN TABLETS (ORAL)	ON	Yes-Generic
PROQUIN XR (ORAL)	OFF	No
NOROXIN (ORAL)	OFF	No
CIPROFLOXACIN ER (ORAL)	OFF	No-Generic
AVELOX (ORAL)	ON	Yes
LEVAQUIN (ORAL)	OFF	No
OFLOXACIN (ORAL)	OFF	No-Generic
CIPRO SUSPENSION (ORAL)	OFF	No

No public testimony on this class was provided. Jack Putman M.D. yielded is time-back to the Committee on behalf of Merck.

Dr. Dickey made a motion to accept the recommendations as presented. The motion was seconded by Dr. Tingle and passed unanimously by the Committee.

HEPATITIS C AGENTS

Mr. Wuest provided an overview of the class including a recent study comparing Peg-Intron versus Pegasys in which Pegasys proved to be superior.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
PEG-INTRON (SUBCUTANE.)	OFF	No
PEGASYS (SUBCUTANE.)	ON	Yes
PEG-INTRON REDIPEN (SUBCUTANE.)	OFF	No
INFERGEN (SUBCUTANE.)	OFF	No

Public testimony on this class was provided on Peg-Intron by Jack Putman, M.D. on behalf of Merck. Dereck Terry, Pharm.D. from Genentech yielded his time.

Dr. Dickey made a motion to approve the PDL as recommended. The motion was seconded by Ms. Wilbanks and was passed unanimously.

IMMUNOSUPPRESSIVES, ORAL

Mr. Wuest presented clinical data on agents in this class with was a new class to be reviewed by the Committee.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
CELLCEPT (ORAL)	NA	Yes
AZATHIOPRINE (ORAL)	NA	Yes-Generic
MYCOPHENOLATE MOFETIL (ORAL)	NA	Yes-Generic
NEORAL (ORAL)	NA	Yes
GENGRAF (ORAL)	NA	Yes
CYCLOSPORINE, MODIFIED (ORAL)	NA	Yes-Generic
SANDIMMUNE (ORAL)	NA	Yes
AZASAN (ORAL)	NA	Yes
PROGRAF (ORAL)	NA	Yes
MYFORTIC (ORAL)	NA	Yes
TACROLIMUS (ORAL)	NA	Yes-Generic
CYCLOSPORINE (ORAL)	NA	Yes-Generic
RAPAMUNE (ORAL)	NA	Yes
ZORTRESS (ORAL)	NA	Yes

Public testimony on this class was provided on Prograf by Marilyn Ripull on behalf of Astellas.

Dr. Dickey made a motion to accept the recommendations as presented. Dr. Brewer seconded the motion, which then passed unanimously.

MACROLIDES-KETOLIDES

Mr. Wuest presented an overview of this class.

He then presented the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
ERYTHROMYCIN (ORAL)	ON	Yes-Generic
AZITHROMYCIN (ORAL)	ON	Yes-Generic
CLARITHROMYCIN (ORAL)	ON	Yes-Generic
ZMAX (ORAL)	OFF	No
CLARITHROMYCIN ER (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Voulters made a motion to accept the recommendations as presented. Ms. Wilbanks seconded the motion, which then passed unanimously.

OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
TOBRADEX SOLUTION (OPHTHALMIC)	NA	Yes
NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)	NA	Yes-Generic
POLY-PRED (OPHTHALMIC)	NA	Yes
ZYLET (OPHTHALMIC)	NA	Yes
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	NA	Yes-Generic
TOBRADEX OINTMENT (OPHTHALMIC)	NA	Yes
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	NA	Yes-Generic
PRED-G (OPHTHALMIC)	NA	Yes
TOBRAMYCIN / DEXAMETHASONE SOLUTION (OPHTHALMIC)	NA	Yes-Generic
NEOMYCIN/POLYMYXIN/HC (OPHTHALMIC)	NA	Yes-Generic

No public testimony on this class was provided.

Dr. Tingle made a motion to approve the recommendations. The motion was seconded by Dr. Voulters. The motion was approved unanimously.

OPHTHALMIC ANTIBIOTICS

Mr. Wuest provided an overview of the class.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
SULFACETAMIDE (OPHTHALMIC)	ON	Yes-Generic
TOBRAMYCIN (OPHTHALMIC)	ON	Yes-Generic
GENTAMICIN (OPHTHALMIC)	ON	Yes-Generic
POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	ON	Yes-Generic
AZASITE (OPHTHALMIC)	ON	Yes
ERYTHROMYCIN (OPHTHALMIC)	ON	Yes-Generic
VIGAMOX (OPHTHALMIC)	ON	Yes
TOBREX OINTMENT (OPHTHALMIC)	ON	Yes
BESIVANCE (OPHTHALMIC)	OFF	No
OFLOXACIN (OPHTHALMIC)	OFF	No-Generic
TRIPLE ANTIBIOTIC (OPHTHALMIC)	ON	Yes-Generic
ZYMAR (OPHTHALMIC)	OFF	No
BACITRACIN/POLYMYXIN (OPHTHALMIC)	ON	Yes-Generic
CILOXAN OINTMENT (OPHTHALMIC)	OFF	No
QUIXIN (OPHTHALMIC)	OFF	No
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	OFF	No-Generic
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	ON	Yes-Generic
BACITRACIN (OPHTHALMIC)	ON	Yes-Generic
IQUIX (OPHTHALMIC)	ON	Yes
ZYMAXID (OPHTHALMIC)	OFF	No
NATACYN (OPHTHALMIC)	OFF	No

No public testimony on this class was provided.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Dickey and passed unanimously.

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

Mr. Wuest provided an overview of the class including a policy change make ketotifen OTC preferred.

Mr. Wuest presented the following recommendations:

Brand Name	Current PDL Status	PDL Recommendation
OPTIVAR (OPHTHALMIC)	ON	Yes
ALREX (OPHTHALMIC)	ON	Yes
KETOTIFEN OTC (OPHTHALMIC)	ON	Yes-Generic
PATANOL (OPHTHALMIC)	ON	Yes
PATADAY (OPHTHALMIC)	ON	Yes
ACULAR (OPHTHALMIC)	OFF	No
CROMOLYN SODIUM (OPHTHALMIC)	ON	Yes-Generic
EMADINE (OPHTHALMIC)	ON	Yes
ALOMIDE (OPHTHALMIC)	OFF	No
ALAMAST (OPHTHALMIC)	OFF	No
ALOCRIAL (OPHTHALMIC)	OFF	No
ELESTAT (OPHTHALMIC)	ON	Yes
KETOROLAC (OPHTHALMIC)	OFF	No-Generic
AZELASTINE (OPHTHALMIC)	ON	Yes-Generic
BEPREVE (OPHTHALMIC)	OFF	No

No public testimony on this class was provided.

Dr. Dickey made a motion to accept the recommendations as presented. The motion was seconded by D. Brewer and passed unanimously.

OPHTHALMICS, ANTI-INFLAMMATORIES

Mr. Wuest provided an overview of the class.

Mr. Wuest presented the following recommendations:

Brand Name	Current PDL Status	PDL Recommendation
ACUVAIL (OPHTHALMIC)	OFF	No
FLURBIPROFEN (OPHTHALMIC)	ON	Yes-Generic
FLUOROMETHOLONE (OPHTHALMIC)	ON	Yes-Generic
FML S.O.P. (OPHTHALMIC)	ON	Yes
LOTEMAX (OPHTHALMIC)	ON	Yes
FML FORTE (OPHTHALMIC)	ON	Yes

PRED MILD (OPHTHALMIC)	OFF	No
FLAREX (OPHTHALMIC)	ON	Yes
MAXIDEX (OPHTHALMIC)	ON	Yes
DEXAMETHASONE (OPHTHALMIC)	ON	Yes-Generic
DICLOFENAC (OPHTHALMIC)	ON	Yes-Generic
XIBROM (OPHTHALMIC)	OFF	No
VEXOL (OPHTHALMIC)	ON	Yes
NEVANAC (OPHTHALMIC)	ON	Yes
KETOROLAC LS (OPHTHALMIC)	OFF	No-Generic
DUREZOL (OPHTHALMIC)	OFF	No

No public testimony on this class was provided.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Mr. Hicks and passed unanimously.

OPHTHALMICS, GLAUCOMA AGENTS

Mr. Wuest provided an overview of the class including as comparison for Travatan versus Xalatan.

Mr. Wuest presented two models of the cost sheets, the following version was recommended by the Committee:

Brand Name	Current PDL Status	<i>PDL Recommendation</i>
COSOPT (OPHTHALMIC)	ON	Yes
TRUSOPT (OPHTHALMIC)	ON	Yes
LEVOBUNOLOL (OPHTHALMIC)	ON	Yes-Generic
METIPRANOLOL (OPHTHALMIC)	ON	Yes-Generic
PILOCARPINE (OPHTHALMIC)	ON	Yes-Generic
BETIMOL (OPHTHALMIC)	ON	Yes
TIMOLOL (OPHTHALMIC)	ON	Yes-Generic
ISTALOL (OPHTHALMIC)	ON	Yes
CARTEOLOL (OPHTHALMIC)	ON	Yes-Generic

LUMIGAN 2.5ML (OPHTHALMIC)	OFF	No
TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	ON	Yes
XALATAN 2.5 ML (OPHTHALMIC)	ON	Yes
BRIMONIDINE (OPHTHALMIC)	ON	Yes-Generic
AZOPT (OPHTHALMIC)	ON	Yes
BETAXOLOL (OPHTHALMIC)	ON	Yes-Generic
PROPINE (OPHTHALMIC)	OFF	No
COMBIGAN (OPHTHALMIC)	ON	Yes
ALPHAGAN P (OPHTHALMIC)	OFF	No
BETOPTIC S (OPHTHALMIC)	OFF	No
LUMIGAN 5ML (OPHTHALMIC)	OFF	No
DORZOLAMIDE (OPHTHALMIC)	ON	Yes-Generic
TRAVATAN / TRAVATAN Z 5 ML (OPHTHALMIC)	ON	Yes
BRIMONIDINE P (OPHTHALMIC)	OFF	No-Generic
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	ON	Yes-Generic
LUMIGAN 7.5ML (OPHTHALMIC)	OFF	No

No public testimony on this class was provided.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Ms. Wilbanks and passed unanimously.

OTIC ANTIBIOTICS

Mr. Wuest provided an overview of the class.

Mr. Wuest presented the following recommendations:

Brand Name	Current PDL Status	PDL Recommendation
NEOMYCIN/POLYMYXIN/HC (OTIC)	ON	Yes-Generic
COLY-MYCIN S (OTIC)	ON	Yes
CETRAXAL (OTIC)	ON	Yes
CORTISPORIN-TC (OTIC)	ON	Yes
CIPRODEX (OTIC)	ON	Yes
CIPRO HC (OTIC)	OFF	No

OFLOXACIN (OTIC)	OFF	No-Generic
------------------	-----	------------

No public testimony on this class was provided.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Dr. Dickey and passed unanimously

STIMULANTS AND RELATED AGENTS

Mr. Wuest provided an overview of the class.

Mr. Wuest presented the following recommendations:

Brand Name	Current PDL Status	PDL Recommendation
METHYLPHENIDATE (ORAL)	ON	Yes-Generic
FOCALIN (ORAL)	ON	Yes
DEXMETHYLPHENIDATE (ORAL)	ON	Yes-Generic
METHYLPHENIDATE ER (ORAL)	ON	Yes-Generic
FOCALIN XR (ORAL)	ON	Yes
RITALIN LA (ORAL)	OFF	No
VYVANSE (ORAL)	ON	Yes
AMPHETAMINE SALT COMBO (ORAL)	ON	Yes-Generic
ADDERALL XR (ORAL)	ON	Yes
STRATTERA (ORAL)	OFF	No
DAYTRANA (TRANSDERMAL)	ON	Yes
CONCERTA (ORAL)	ON	Yes
METADATE CD (ORAL)	ON	Yes
DEXTROAMPHETAMINE (ORAL)	ON	Yes-Generic
PROCENTRA (ORAL)	OFF	No
METHAMPHETAMINE (ORAL)	OFF	No-Generic
STRATTERA (ORAL)	OFF	No
INTUNIV (ORAL)	ON	Yes
METHYLIN CHEWABLE AND SOLUTION (ORAL)	ON	Yes
AMPHETAMINE SALT COMBO ER (ORAL)	OFF	No-Generic
DESOXYN (ORAL)	OFF	No
PROVIGIL (ORAL)	OFF	No
NUVIGIL (ORAL)	OFF	No

Public testimony on this class was provided on Strattera by Esther Liu on behalf of Lilly and on Intuniv by Jennifer Robinson on behalf of Shire.

Jennifer Robinson, Pharm.D. from Shire and Michele Arledge, Pharm.D. from Ortho-McNeil Janssen yielded their time to the Committee. After Committee discussion of non-stimulants used in treatment for ADHD/ADD, Dr. Robinson spoke on behalf of Intuniv.

Dr. Tingle made a motion to accept the recommendations as presented with the addition of Strattera as preferred. Dr. Brewer seconded the motion, which then passed unanimously.

TETRACYCLINES

Mr. Wuest provided an overview of the class including the many dosage form available in the class.

Mr. Wuest presented the following recommendations:

Brand Name	Current PDL Status	PDL Recommendation
DOXYCYCLINE HYCLATE (ORAL)	ON	Yes-Generic
TETRACYCLINE (ORAL)	ON	Yes-Generic
VIBRAMYCIN SUSPENSION (ORAL)	OFF	No
MINOCYCLINE CAPSULES (ORAL)	ON	Yes-Generic
DOXYCYCLINE MONOHYDR.ATE (ORAL)	ON	Yes-Generic
ORACEA (ORAL)	OFF	No
DOXYCYCLINE HYCLATE DR. (ORAL)	ON	Yes-Generic
NUTRIDOX (ORAL)	OFF	No
DORYX (ORAL)	OFF	No
MINOCYCLINE TABLETS (ORAL)	ON	Yes-Generic
MINOCYCLINE ER (ORAL)	OFF	No-Generic
ADOXA TT (ORAL)	OFF	No
ADOXA CK (ORAL)	OFF	No
SOLODYN (ORAL)	OFF	No
MINOCYCLINE HCL (ORAL)	OFF	No-Generic
DEMECLOCYCLINE (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Ms. Wilbanks and passed unanimously.

OTHER BUSINESS

There was no other business.

NEXT MEETING DATE

Ms. Clark stated that the next P&T Committee meeting is tentatively scheduled to be October 12th 2010.

ADJOURNMENT

There being no further business, Dr. Minor adjourned the meeting.